Oridonin: A small molecule inhibitor of cystic fibrosis transmembrane conductance regulator (CFTR) isolated from traditional Chinese medicine

被引:8
|
作者
Luan, Jian [1 ]
Zhang, Yaofang [1 ]
Yang, Shuang [1 ]
Wang, Xue [1 ]
Yu, Bo [1 ]
Yang, Hong [1 ]
机构
[1] Liaoning Normal Univ, Sch Life Sci, Liaoning Prov Key Lab Biotechnol & Drug Discovery, Dalian 116029, Peoples R China
关键词
Oridonin; Cholera; Traditional Chinese medicine (TCM); High throughput screening (HTS); Cystic fibrosis transmembrane conductance regulator (CFTR); Molecular target; INTESTINAL FLUID SECRETION; VIBRIO-CHOLERAE; MOUSE MODEL; DIARRHEA; THERAPY; CELLS; ENTEROTOXIN; ACTIVATORS; FUTURE;
D O I
10.1016/j.fitote.2014.11.001
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The cystic fibrosis transmembrane conductance regulator (CFTR) is an epithelial chloride channel regulating the transepithelial transport of electrolyte and water. In the recent years, CFTR chloride channel becomes the new molecular target of treating secretory diarrhea. The objective of this study is to find out a novel CFTR inhibitor from traditional Chinese medicine (TCM) and study on its pharmacological activity. About 34,000 factions of TCM extracts were screened by high throughput screening (HTS) in this research. We found that Rabdosia rubescens show a potent inhibition on CFTR. Under the bio-active analysis guidance, an ent-kaurane diterpenoid - oridonin (PubChem CID: 34378) was isolated from R rubescens. A series of intensive studies showed that oridonin remarkably reduced iodide influx in wt-CFTR and Delta F508-CFTR FRT epithelial cells in a dose-dependent and irreversible way. Oridonin sharply blocked FSK-stimulated short-circuit current in both rats and mice intestine in vitro. In mouse closed-loop model, oridonin reduced cholera toxin-induced fluid secretion significantly over 6 hours in vivo. Thus we concluded that oridonin is a new inhibitor of CFTR Cl channel. It will be a good leading compound for developing the new drug of cholera toxin-induced secretory diarrhea. (C) 2014 Elsevier B.V. All rights reserved.
引用
收藏
页码:88 / 94
页数:7
相关论文
共 50 条
  • [1] Small molecule modulators of cystic fibrosis transmembrane conductance regulator (CFTR): Structure, classification, and mechanisms
    Cao, Luyang
    Wu, Yong
    Gong, Yanchun
    Zhou, Qingfa
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 265
  • [2] Cystic fibrosis transmembrane conductance regulator (CFTR): beyond cystic fibrosis
    Parisi, Giuseppe Fabio
    Mollica, Federico
    Giallongo, Alessandro
    Papale, Maria
    Manti, Sara
    Leonardi, Salvatore
    EGYPTIAN JOURNAL OF MEDICAL HUMAN GENETICS, 2022, 23 (01)
  • [3] Cystic fibrosis transmembrane conductance regulator (CFTR): beyond cystic fibrosis
    Giuseppe Fabio Parisi
    Federico Mòllica
    Alessandro Giallongo
    Maria Papale
    Sara Manti
    Salvatore Leonardi
    Egyptian Journal of Medical Human Genetics, 23
  • [4] CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR)
    HIGGINS, CF
    BRITISH MEDICAL BULLETIN, 1992, 48 (04) : 754 - 765
  • [5] Pharmacology of CFTR (cystic fibrosis transmembrane conductance regulator)
    Cuthbert, A. W.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2004, 18 : 22 - 22
  • [6] The cystic fibrosis transmembrane conductance regulator (CFTR) and its stability
    Meng, Xin
    Clews, Jack
    Kargas, Vasileios
    Wang, Xiaomeng
    Ford, Robert C.
    CELLULAR AND MOLECULAR LIFE SCIENCES, 2017, 74 (01) : 23 - 38
  • [7] The cystic fibrosis transmembrane conductance regulator (CFTR) and its stability
    Xin Meng
    Jack Clews
    Vasileios Kargas
    Xiaomeng Wang
    Robert C. Ford
    Cellular and Molecular Life Sciences, 2017, 74 : 23 - 38
  • [8] Purification and crystallization of the cystic fibrosis transmembrane conductance regulator (CFTR)
    Rosenberg, MF
    Kamis, AB
    Aleksandrov, LA
    Ford, RC
    Riordan, JR
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (37) : 39051 - 39057
  • [9] Regulation of neurosecretion by the cystic fibrosis transmembrane conductance regulator (CFTR).
    Weyler, RT
    Altschuler, SM
    Mulberg, AE
    JOURNAL OF INVESTIGATIVE MEDICINE, 1998, 46 (03) : 207A - 207A